VISTAPH
Vista Pharmaceuticals financials
- Market cap
- ₹45 Cr
Quarterly results
Q1 FY27: revenue down 100.0%, net profit up 23.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 2 | 1 −41% | 2 −5% | 0 −100% | 0 −100% |
| EBITDA | -1 | -2 | -1 | -1 | -3 −313% | -3 −97% | -7 −676% | -1 +24% |
| Net profit | -1 | -1 | -1 | -1 | -3 −167% | -2 −76% | -6 −291% | -1 +23% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −42.2% 1Y
1Y: ₹10.06 on 9 Sept 2025 → ₹5.81. High ₹10.24 (26 Sept 2025), low ₹5.8 (2 Mar 2026).
Financials, as filed
Revenue fell 27.5% a year over 2 years, FY24 to FY26. Operating margin narrowed to -270.4%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹10 Cr | ₹10 Cr | ₹5 Cr |
| Operating profit | ₹-4 Cr | ₹-4 Cr | ₹-15 Cr |
| Operating margin | -34.7% | -40.1% | -270.4% |
| Interest | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Depreciation | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Net profit | ₹-5 Cr | ₹-5 Cr | ₹-12 Cr |
| Net margin | -43.9% | -46.1% | -223.3% |
| Cash from operations | ₹-5 Cr | ₹-7 Cr | ₹-4 Cr |
| Free cash flow | ₹-6 Cr | ₹-7 Cr | ₹-5 Cr |
| ROCE | -8.0% | -9.0% | -30.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹7 Cr | ₹7 Cr | ₹8 Cr | ₹9 Cr | ₹12 Cr | ₹12 Cr |
| Reserves | ₹25 Cr | ₹28 Cr | ₹29 Cr | ₹31 Cr | ₹32 Cr | ₹24 Cr |
| Borrowings | ₹11 Cr | ₹13 Cr | ₹10 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr |
| Other liabilities | ₹9 Cr | ₹8 Cr | ₹9 Cr | ₹10 Cr | ₹8 Cr | ₹9 Cr |
| Total liabilities | ₹53 Cr | ₹56 Cr | ₹56 Cr | ₹58 Cr | ₹61 Cr | ₹55 Cr |
| Fixed assets | ₹20 Cr | ₹19 Cr | ₹20 Cr | ₹19 Cr | ₹19 Cr | ₹18 Cr |
| Capital work in progress | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹10 Cr | ₹11 Cr | ₹11 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹24 Cr | ₹27 Cr | ₹27 Cr | ₹29 Cr | ₹32 Cr | ₹26 Cr |
| Total assets | ₹53 Cr | ₹56 Cr | ₹56 Cr | ₹58 Cr | ₹61 Cr | ₹55 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025.
- Promoters
- 21.2%
- DIIs
- 0.0%
- Public
- 78.8%
Since Jun 2025
- Public +0.02 pp
- Promoters 0.00 pp
- DIIs 0.00 pp
How it drifted, 12 quarters
Over this window the public went from 70.5% to 78.8% — +8.3 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 29.5%, DIIs 0.0%, Public 70.5%.Dec '23: Promoters 27.8%, DIIs 0.0%, Public 72.2%.Mar '24: Promoters 27.8%, DIIs 0.0%, Public 72.2%.Jun '24: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Sep '24: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Dec '24: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Mar '25: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Jun '25: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Sep '25: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Dec '25: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Mar '26: Promoters 21.2%, DIIs 0.0%, Public 78.8%.Jun '26: Promoters 21.2%, DIIs 0.0%, Public 78.8%.
Who is on the register
Named in the Jun 2026 filing
Every holder of Vista Pharmaceuticals Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Murali Meraga | 14.62% | unchanged |
| Pavan Sathvik Gilaka | 12.60% | unchanged |
| Umakanth Katta | 12.25% | unchanged |
| Vista Pharmaceuticals Inc | 10.69% | unchanged |
| Dhananjaya Alli | 4.69% | unchanged |
| Suresh Gadalay | 4.64% | unchanged |
| Kamal Gadalay | 3.03% | unchanged |
| Vasant V Alli | 2.60% | unchanged |
| Deepthi Pachipala | 2.44% | unchanged |
| Chittajallu Naga Keerthi | 2.44% | unchanged |
| Keshava Murthy Shiva Shankar | 2.04% | unchanged |
| Telangana State Industrial Development Corporation Limited | 1.22% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Vista Pharmaceuticals Ltd.
Guides on how to read this kind of business and the numbers that matter.